Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart

Martin, Cindy M.; Meeson, Annette; Robertson, Scott; Hawke, Thomas J.; Richardson, James A.; Bates, Susan E.; Goetsch, Sean C.; Gallardo, Teresa; Garry, Daniel J.

doi:10.1016/j.ydbio.2003.09.028

Cited by 623 publications

(480 citation statements)

References 41 publications

Supporting

Mentioning

451

Contrasting

Unclassified

Order By: Relevance

“…SP cells with stem cell-like properties in adult hearts were first reported by Hierlihy et al (2002). Since then, several groups, including ours, have confirmed the presence of such stem/progenitor cell populations in adult hearts (Martin et al, 2004;Pfister et al, 2005;Oyama et al, 2007;Liang et al, 2010).…”

Section: Resident Cscs Sca1 1 /Cd31 2 Cardiac Sp Cellssupporting

confidence: 62%

Migration of Resident Cardiac Stem Cells in Myocardial Infarction

Liang

Phillips

2012

The Anatomical Record

View full text Add to dashboard Cite

Ischemic heart disease is a major cause of morbidity and mortality worldwide. Stem cell-based therapy, which aims to restore cardiac structure and function by regeneration of functional myocardium, has recently been proposed as a novel alternative treatment modality. Resident cardiac stem cells (CSCs) in adult hearts are a key cell type under investigation. CSCs have been shown to be able to repair damaged myocardium and improve myocardial function in both human and animal studies. This approach relies not only on the proliferation of the CSCs, but also upon their migration to the site of injury within the heart. Here, we briefly review reported CSC populations and discuss signaling factors and pathways required for the migration of CSCs. Anat Rec, 296:184-191, 2013. V C 2012 Wiley Periodicals, Inc.

show abstract

Section: Resident Cscs Sca1 1 /Cd31 2 Cardiac Sp Cellssupporting

confidence: 62%

Migration of Resident Cardiac Stem Cells in Myocardial Infarction

Liang

Phillips

2012

The Anatomical Record

View full text Add to dashboard Cite

show abstract

“…In the bone marrow, the SP defines a cell subset with a highly homogeneous content of haematopoietic stem cells (HSCs) [69]. Similar SP cells have been detected in various organs, such as skeletal muscle [70], lung [71]; heart [72] and kidney [73,74]. Inowa et al [75] reported that an adult kidney SP fraction also exists in humans.…”

Section: Progenitors Isolated Based Upon Cellular Behaviourmentioning

confidence: 94%

Stem cell options for kidney disease

Hopkins

Rae

et al. 2008

The Journal of Pathology

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is increasing at the rate of 6-8% per annum in the US alone. At present, dialysis and transplantation remain the only treatment options. However, there is hope that stem cells and regenerative medicine may provide additional regenerative options for kidney disease. Such new treatments might involve induction of repair using endogenous or exogenous stem cells or the reprogramming of the organ to reinitiate development. This review addresses the current state of understanding with respect to the ability of non-renal stem cell sources to influence renal repair, the existence of endogenous renal stem cells and the biology of normal renal repair in response to damage. Understanding repair options via an understanding of renal developmentThe prevalence and incidence of chronic kidney disease (CKD) is increasing at 6-8% per annum in the USA alone, largely as a result of increased prevalence of diabetes and obesity [1]. To understand what might be possible with respect to cellular therapies or regenerative medicine for the kidney, one first needs to consider what is understood about normal renal development and response to injury. The kidney has been classically regarded as an organ with minimal cellular turnover and no capacity for regeneration. The subsequent identification of stem cells in a number of such organs, including the brain, has challenged this view. However, the dogma remains that the kidney reaches a maximal complement of nephrons and then loses these over time [2]. This dogma is drawn from our understanding of the development of this organ. The progenitor population during developmentThe kidney is mesodermal in origin and develops from two populations derived from intermediate mesoderm, the ureteric bud (UB) and the metanephric mesenchyme (MM). While an even broader potential had been proposed [3], genetic and lineage analyses have confirmed that the MM gives rise to all portions of the nephron other than the collecting ducts and also gives rise to elements of the renal interstitium [4][5][6]. The UB gives rise to the ureter and collecting ducts only. The MM is apparently not homogeneous but forms condensed mesenchyme around the tips of the branching UB. This cap mesenchyme (CM) contains self-renewing progenitors capable of generating all cells of the nephron other than the collecting ducts via an initial mesenchyme-epithelial transition (MET) event throughout the prenatal developmental period [6]. The continued expression of the transcription factor Six2 in CM is required for maintenance of this stem cell population during kidney development [5]. As the UB branches and extends through the MM, individual MET events occur at the underside of each tip to form a new nephron [2]. This nephron endowment therefore proceeds from the centre of the kidney out to the periphery, with the CM stem cell field remaining on the outer edge of the expanding organ. Endowment of new nephrons is restricted to prenatal development in humans, while in rodents it persists only until the imm...

show abstract

“…14, 15 Hierlihy et al 14 were the first to demonstrate the presence of a verapamil-sensitive SP cell in the postnatal mouse heart. Shortly thereafter, Martin et al 15 attributed the cardiac SP phenotype to Abcg2 protein expression and showed that a population of SP cells persisted into adulthood in the mouse. When selected, adult mouse SP cells also could differentiate into α-actinin-positive cells when cocultured with primary cardiomyocytes.…”

Section: Sp Cardiac Stem Cellsmentioning

confidence: 99%

Stem cells in the heart: What's the buzz all about?—Part 1: Preclinical considerations

et al. 2008

View full text Add to dashboard Cite

New approaches for cardiac repair have been enabled by the discovery that the heart contains its own reservoir of stem cells. These cells are positive for various stem/progenitor cell markers, are selfrenewing, and exhibit multilineage differentiation potential. Recently we developed a method for ex vivo expansion of cardiac-derived stem cells from human myocardial biopsies with a view to subsequent autologous transplantation for myocardial regeneration. Here we review the state of the cardiac stem cell field and our own work on cardiosphere-derived stem cells from human hearts. The first of this two-part review outlines emerging preclinical data on the application of cardiac stem cells. Part 2 continues with a discussion of other stem cell sources with clinical potential, a summary of the critical issues surrounding stem cell therapy (with an emphasis on the crucial issue of how cell transplantation may influence arrhythmias), our perception of clinical stem cell trials to date, and the issues facing the clinical application of cardiac stem cells.

show abstract

Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart

Cited by 623 publications

References 41 publications

Migration of Resident Cardiac Stem Cells in Myocardial Infarction

Migration of Resident Cardiac Stem Cells in Myocardial Infarction

Stem cell options for kidney disease

Stem cells in the heart: What's the buzz all about?—Part 1: Preclinical considerations

Contact Info

Product

Resources

About